Skip to main content
Equibles
KURA logo

KURA

Kura Oncology, Inc.
$10.86 -0.03 (-0.28%) At close · Jul 17
Market Cap
$964.09M
Shares
88,774,365

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.86 Open$10.64 Day$10.50–10.99 52W$5.45–12.49 Avg vol 30d1.8M Short int15.1M · 17.0% float · 8.6d Short vol57% Last earningsMay 12, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 12
Up next
Next earnings call
Aug 14, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 16.7 · calm Equity put/call 0.67
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +13%
      above
      Price vs 50-day avg +7%
      above
      RSI (14) 52
      neutral
      MACD trend Negative
      52-week position 77%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +13%
      trailing
      6-month return +26%
      trailing
      YTD return +5%
      this year
      Relative strength +17%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $10 › 200d $10 — 50d above 200d
      Institutional flow Accumulating
      17 of 219 funds reported for Jun 30 · net +442.8K sh shares · +2 new
      Insider flow Distributing
      Net -$154.8K over 90 days · 100% sells
      Short interest Rising
      17.00% of float · ▲ +3.4% MoM · 8.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      219 holders — near 3-yr high, broad support
      Squeeze score 78
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth +25%
      Y/Y
      EPS growth −57%
      Y/Y
      Free cash flow $-70.7M
      Balance sheet $139.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 61%
      annualized · 1-yr
      Max drawdown −39%
      past year
      ATR 5.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +13% Bullish
      Price vs 50-day avg
      +7% Bullish
      RSI (14)
      52 Neutral
      MACD trend
      Negative Bearish
      52-week position
      77% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $10 › 200d $10 — 50d above 200d
      Institutional flow Accumulating
      17 of 219 funds reported for Jun 30 · net +442.8K sh shares · +2 new
      Insider flow Distributing
      Net -$154.8K over 90 days · 100% sells
      Short interest Rising
      17.00% of float · ▲ +3.4% MoM · 8.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      219 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $5 Now $11 · 77% 52-wk high $12
      vs 200-day avg +13% vs 50-day avg +7%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      New patient starts 85 Q1 2026 —
      Total prescriptions 157 Q1 2026 —
      Cash, cash equivalents, and short-term investments $667.3M as of December 31, 2025 —
      Milestone payments under collaboration agreement with Kyowa Kirin $195M Q4 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      KURA
      Kura Oncology, Inc.
      this stock
      		$964.09M +4.5% +25.2% — 17.0%
      ONC
      BeOne Medicines Ltd.
      		 $458.76B +4.5% +22179.2% 933.6 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.36B +7.2% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $71.18B -11.9% +20.8% 16.6 3.3%
      ARGX
      Argenx SE
      		 $53.68B +2.0% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      220
      % held
      94.7%
      Reported
      17 of 219
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      167
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      15.1M
      Days to cover
      8.6d
      Change
      +489.4K sh
      View
      Short Volume
      Short vol %
      57%
      As of
      Jul 17, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.6K
      Value
      $28.6K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      50.7%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$154.8K
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Christopher L. Jacobs
      Amount
      $1.0K–$15.0K
      Traded
      Dec 12, 2022
      View
      Financials
      Financials
      Revenue (FY)
      $67.5M
      Net income (FY)
      $-278.7M
      EPS diluted
      $-3.18
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 4, 2026
      This year
      8
      View
      Proposed Sales
      Value
      $812.8K
      Shares
      84.9K
      Filed
      Jun 18, 2026
      View
      Exempt Offerings
      Offering
      $150.0M
      Filed
      Feb 5, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      KURA -5.2% +13.5% +25.8% -1.0% +4.5%
      SPY -0.1% +0.1% +9.0% +0.5% +10.1%
      vs SPY -5.0% +13.4% +16.9% -1.5% -5.6%
      Key facts CIK 1422143 CUSIP 50127T109 13F (30d) 17 filings 17 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)